Evidence map›Paper›PMID 29851537›Full record

ArticleJournal of managed care & specialty pharmacy2018

Viscosupplementation for Osteoarthritis of the Knee: A Key Opinion Leader Panel Discussion.

Jack Bert, Jim Kenney, Nicholas A Sgaglione, Scott McClelland, Robert Brophy, John Toth, Joseph Ruane, Yousaf Ali, Sheila Arquette, Vinod Dasa and 1 more

Open access · bronzeAbstract readValidation Study
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jack Bert1 University of Minnesota School of Medicine, Minneapolis.
Jim Kenney2 Harvard Pilgrim Healthcare, Wellesley, Massachusetts.
Nicholas A Sgaglione3 Northwell Health Orthopaedics, Great Neck, New York.
Scott McClelland4 Florida Blue, Jacksonville.
Robert Brophy5 Washington University School of Medicine, St. Louis, Missouri.
John Toth6 Yale Health, New Haven, Connecticut.
Joseph Ruane7 McConnell Spine, Sport, and Joint Center, Columbus, Ohio, and Ohio University College of Osteopathic Medicine, Athens.
Yousaf Ali8 Icahn School of Medicine at Mt. Sinai, New York, New York.
Sheila Arquette9 Independent Health, Buffalo, New York.
Vinod Dasa10 Louisiana State University Health Sciences Center, New Orleans; Oschner Kenner Medical Center, Kenner, Louisiana; Vector Medical, Boca Raton, Florida; and Touro University Nevada College of Osteopathic Medicine, Henderson, Nevada.
Maria Lopes11 Magellan Rx Management.
Icahn School of Medicine at Mount Sinai · USUniversity of Minnesota · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With a sharp rise in the prevalence of osteoarthritis of the knee (OAK) in a younger population, new management strategies are needed to preserve mobility, improve patients' quality of life, and reduce the effects of potential disease-related comorbidities. Viscosupplementation with the use of hyaluronic acid (HA) injection is a treatment option for OAK that can provide lubrication and elastic shock absorption, leading to potential pain relief, improved function, and reduced stiffness. A key opinion leader (KOL) panel discussion was held December 3, 2016, with the objective of sharing opinions, ideas, information, and trends regarding OAK and the potential treatment and management offered by viscosupplementation. The panel concluded that viscosupplementation with HA injections presents a viable, cost-effective, and safe alternative for the treatment of OAK. DISCLOSURES: This panel discussion and report was facilitated by Magellan Rx Manage-ment and funded by Sanofi. Bert and Ruane report fees from Sanofi outside of this project. Sgaglione reports royalty payments from Zimmer Biomet and Wolters Kluwer. Dasa has received fees from Bioventus and Myoscience. All the authors received an honorarium for work on this project. Lopes is employed by Magellan Rx Management.

Indexed as

AttitudeCost-Benefit AnalysisCost of IllnessHumansHyaluronic AcidOsteoarthritis, KneePractice Guidelines as TopicPrevalenceProfessional Practice GapsQuality of LifeTreatment OutcomeUnited StatesViscosupplementationHyaluronic Acid

Identifiers

PMID29851537
PMCPMC10408395
OpenAlexW2806134382

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.